Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Patrizia Mondello, MD PhD MSc, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Alberto Arribas, PhD, Andrea Rinaldi, Anas Younes, MD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2858.

https://doi.org/10.1182/blood-2019-125123

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Andrea Tomirotti, PhD, Giuseppe Merlino, Alessio Fiascarelli, PhD, Simone Baldini, MD, Alessia Tagliavini, Elisa Borella, Milena Mazan, PhD, Krzysztof Brzózka, PhD, Alessandro Bressan, Andrea Pellacani, PhD MD, Massimiliano Salerno, Monica Binaschi, PhD, Daniela Bellarosa

Blood (2019) 134 (Supplement_1): 5087.

https://doi.org/10.1182/blood-2019-124800

Published: 2019

Journal Articles

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Blood (2019) 134 (Supplement_1): 4220.

https://doi.org/10.1182/blood-2019-128165

Published: 2019

Journal Articles

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Ayako Nogami, MD PhD BPharm, Daisuke Watanabe, MD, Keigo Okada, MD, PhD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Toshikage Nagao, MD, PhD, Shuji Tohda, MD, PhD, Osamu Miura, MD, PhD

Blood (2019) 134 (Supplement_1): 1425.

https://doi.org/10.1182/blood-2019-123183

Published: 2019

Journal Articles

PIM Inhibitor SMI-4a Induces Cell Apoptosis and Cell Cycle Arrest in B-Cell Acute Lymphocytic Leukemia Cells Via the JAK2/STAT3 Pathway

Xingyi Kuang, Jie Xiong, Weili Wang, Xinyao Li, Tingting Lu, Jishi Wang, PhD

Blood (2018) 132 (Supplement 1): 4083.

https://doi.org/10.1182/blood-2018-99-117804

Published: 2018

Journal Articles

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

Dipmoy Nath, PhD, Avik Dutta, MSc, Yue Yang, BS, Clifford Whatcott, PhD, Steven L. Warner, PhD, Golam Mohi, PhD

Blood (2018) 132 (Supplement 1): 54.

https://doi.org/10.1182/blood-2018-99-119421

Published: 2018

Journal Articles

Clinical Significance of Pim-2 , PD-1 and PD-L1 Expressions in Multiple Myeloma

Tingting Zhao, MD, Yu Wu, MD

Blood (2018) 132 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2018-99-112004

Published: 2018

Journal Articles

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Takeshi Harada, MD PhD, Asuka Oda, PhD, Yohann Grondin, PhD, Jumpei Teramachi, DDS, PhD, Ariunzaya Bat-Erdene, MD PhD, Masami Iwasa, MD, Masahiro Oura, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Shiro Fujii, MD, Hirokazu Miki, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2018-99-114086

Published: 2018

Journal Articles

Potentially Inappropriate Medication Use in Elderly Patients with Diffuse Large B-Cell Lymphoma Predicts Inferior Survival and Treatment-Related Toxicities

Richard J Lin, MDPhD, Helen Ma, MD, Robin Guo, MD, Andrea Troxel, ScD, Catherine S Diefenbach

Blood (2017) 130 (Supplement 1): 3465.

https://doi.org/10.1182/blood.V130.Suppl_1.3465.3465

Published: 2017

Journal Articles

Pan-PIM Kinase Inhibitors Enhance Lenalidomide's Anti-Myeloma Activity Via Cereblon-IKZF1/3 Cascade

Yonggang Sha, PhD, Jing Zheng, PhD, Jianda Hu, Prof MDPhD, Yubin Kang, MD

Blood (2017) 130 (Supplement 1): 1820.

https://doi.org/10.1182/blood.V130.Suppl_1.1820.1820

Published: 2017

Journal Articles

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Kshama A. Doshi, PhD, Shivani Kapoor, MS, Ying Zou, MD PhD, Xiang Li, PhD, Mario Scarpa, MS, Nidal Muvarak, PhD, Pratik Nagaria, PhD, Olga Goloubeva, PhD MSc, Adriana E. Tron, PhD, Charles J. Bieberich, PhD, Feyruz V. Rassool, BSc, PhD, Maria R. Baer, MD

Blood (2017) 130 (Supplement 1): 1243.

https://doi.org/10.1182/blood.V130.Suppl_1.1243.1243

Published: 2017

Journal Articles

Cytokine Activation of JAK Kinases Rescues FLT3-Mutant AML from FLT3 Inhibition and Requires PIM Kinases

Pamela J. Sung, MD PhD, Holly K. Koblish, PhD, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2017) 130 (Supplement 1): 1250.

https://doi.org/10.1182/blood.V130.Suppl_1.1250.1250

Published: 2017

Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Michael Byrne, MD, William Donnellan, Manish R Patel, MD, Amer M. Zeidan, MD, Mohamad Cherry, MDMS, Maria R. Baer, MD, Amir T. Fathi, MD MD BS, Jason Kaplan, MD, Feng Zhou, Fred Zheng, MD, April M. Barbour, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 2585.

https://doi.org/10.1182/blood.V130.Suppl_1.2585.2585

Published: 2017

Journal Articles

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

Qingxiao Chen, MS, Jingsong He, MD, Huiyao Gu, Xi Huang, MD, Jing Chen, MD, Zhang En Fan, Xing Guo, MD, Haimeng Yan, He Huang, MD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 3079.

https://doi.org/10.1182/blood.V130.Suppl_1.3079.3079

Published: 2017

Journal Articles

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Lucia Mazzacurati, Que T. Lambert, Robert J. Collins, Holly K. Koblish, PhD, Bruce Ruggeri, Matthew C. Stubbs, Gary W. Reuther, PhD

Blood (2017) 130 (Supplement 1): 1661.

https://doi.org/10.1182/blood.V130.Suppl_1.1661.1661

Published: 2017

Journal Articles

Integrated Functional Genomic and Pharmacological Characterization of the Kinome of Myeloma Cells

Ricardo De Matos Simoes, PhD, Eugen Dhimolea, PhD, Ryosuke Shirasaki, MD PhD, Sara Gandolfi, MD, Geoffrey Matthews, PhD, Michal Sheffer, PhD, Olga Dashevsky, PhD, Brian Glassner, PhD, Constantine S. Mitsiades, MD PhD

Blood (2017) 130 (Supplement 1): 2501.

https://doi.org/10.1182/blood.V130.Suppl_1.2501.2501

Published: 2017

Journal Articles

Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma

Maciej Szydłowski, Monika Prochorec-Sobieszek, Anna Szumera-Ciećkiewicz, Edyta Derezińska, Grażyna Hoser, Danuta Wasilewska, Olga Szymańska-Giemza, Ewa Jabłońska, Emilia Białopiotrowicz, Tomasz Sewastianik, Anna Polak, Wojciech Czardybon, Michał Gałęzowski, Renata Windak, Jan Maciej Zaucha, Krzysztof Warzocha, Krzysztof Brzózka, Przemysław Juszczyński

Blood (2017) 130 (12): 1418–1429.

https://doi.org/10.1182/blood-2017-01-760702

Published: 2017

Includes: Supplemental data

Journal Articles

The Pan-PIM Kinase Inhibitor LGB321 Affects Apoptotic Pathways and Microenvironmental Interactions in CLL

Sarah Decker, PhD, Sandra Kissel, Konrad Aumann, MD, Thorsten Zenz, Katja Zirlik, MD, Rainer Claus, MD, Justus Duyster, MD, Christine Dierks, MD

Blood (2016) 128 (22): 4370.

https://doi.org/10.1182/blood.V128.22.4370.4370

Published: 2016

Journal Articles

Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia

Sathish Kumar Reddy Padi, PhD, Libia A Luevano, ND, Ningfei An, PhD, Ritu Pandey, PhD, Neha Singh, PhD, Jin H Song, PhD, Jon C. Aster, MD PhD, Xue-Zhong Yu, PhD, Shikhar Mehrotra, PhD, Andrew S Kraft, MD

Blood (2016) 128 (22): 2742.

https://doi.org/10.1182/blood.V128.22.2742.2742

Published: 2016

NARROW

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

PIM Inhibitor SMI-4a Induces Cell Apoptosis and Cell Cycle Arrest in B-Cell Acute Lymphocytic Leukemia Cells Via the JAK2/STAT3 Pathway

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

Clinical Significance of Pim-2 , PD-1 and PD-L1 Expressions in Multiple Myeloma

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Potentially Inappropriate Medication Use in Elderly Patients with Diffuse Large B-Cell Lymphoma Predicts Inferior Survival and Treatment-Related Toxicities

Pan-PIM Kinase Inhibitors Enhance Lenalidomide's Anti-Myeloma Activity Via Cereblon-IKZF1/3 Cascade

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Cytokine Activation of JAK Kinases Rescues FLT3-Mutant AML from FLT3 Inhibition and Requires PIM Kinases

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Integrated Functional Genomic and Pharmacological Characterization of the Kinome of Myeloma Cells

Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma

The Pan-PIM Kinase Inhibitor LGB321 Affects Apoptotic Pathways and Microenvironmental Interactions in CLL

Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only